newsfilter
← Latest News
Business Wire·

ImmunoGen Announces Multi-Target License and Option Agreement with ImmunoBiochem to Develop Next-Generation Antibody-Drug Conjugates

Collaboration Combines ImmunoGen's Proprietary Linker-Payload Technology with Antibodies Developed by ImmunoBiochem Agreement Grants ImmunoGen an Exclusive License to Existing Antibodies Generated by ImmunoBiochem